NDAINHALATIONAEROSOL, METERED
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
PROAIR HFA (albuterol sulfate) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROAIR HFA is a metered-dose inhaler containing albuterol sulfate, a beta-2 adrenergic agonist approved for treating bronchospasm in asthma and COPD. It works by stimulating beta-2 adrenergic receptors on bronchial smooth muscle, increasing cyclic AMP and causing rapid bronchodilation. Onset of action occurs within 5 minutes with peak effect at approximately 1 hour.
$0.001BPart D
LOE ApproachingProduct approaching end-of-life with modest Part D volume; brand team likely focused on defending market share against generics rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on PROAIR HFA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.